Status:
COMPLETED
D-serine for the Schizophrenia Prodrome
Lead Sponsor:
Nathan Kline Institute for Psychiatric Research
Collaborating Sponsors:
Yale University
The Zucker Hillside Hospital
Conditions:
Schizophrenia Prodrome
Eligibility:
All Genders
13-35 years
Phase:
PHASE2
Brief Summary
The purpose of the study is to determine the safety and efficacy of D-serine as an early intervention treatment for the schizophrenia prodrome condition. This study is a placebo-controlled trial of D-...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- treatment seeking subjects ages 13-35 who meet criteria for the schizophrenia prodrome (see criteria below) and who are able to give written informed assent or consent.
- Subjects must score at least 20 on the Scale of Prodromal Symptoms (SOPS) total score at visit -1.
- Patients may be receiving ongoing treatment with antipsychotic, antidepressant or anti-anxiety medications as prescribed by their treating physician, or may be medication free.
- Patients may enroll in the treatment phase only if they have been on fixed medication dosage for at least 4 weeks. If possible, medication will be held constant during course of study. Subjects will not be excluded or dropped from the study if they have a psychiatric diagnosis or must start a new medication unless the diagnosis is "psychosis". Medication changes and increases or decreases in medication will be permitted at the discretion of the treating physician, and, if they occur, will be treated as secondary outcome measures.
- Exclusion criteria:
- inability to give informed assent or consent,
- history of psychosis (e.g. frank delusions, hallucinations, or thought disorder),
- psychotropic medication begun or dose adjusted within 4 weeks of visit 0,
- contraindication to study medication,
- inclusion symptoms better accounted for by comorbid diagnosis,
- treatment need for comorbid diagnosis outweighs that for prodromal symptoms,
- unstable medical illness,
- females who are of childbearing potential but are not taking adequate contraceptive precautions or who are pregnant or breast feeding,
- alcohol or drug abuse or dependence in the past three months,
- either of the following: Subjects with significant renal disease or estimated GFR below 60 (MDRD, http://www.kidney.org/professionals/kdoqi/gfr\_calculator.cfm) will be excluded (see below for details). Any subject taking or unwilling to avoid other nephrotoxic agents during the course of the study (NSAIDS, ACE inhibitors, ARB's, calcineurin inhibitors, or aminoglycosides) will also be excluded. Therefore, patients will be asked during the study to take acetaminophen (e.g. if they have a headache) and to avoid taking ibuprofen.
- For adolescents (ages 13-17), more stringent renal exclusion criteria will be adhered to:
- estimated GFR is \< 89 cc/min/1.73 m2 as calculated by the Schwartz formula (http://www.kidney.org/professionals/kdoqi/gfr\_calculatorPed.cfm),
- difference of ≥0.3mg/dl between the two baseline serum creatinine values,
- baseline proteinuria defined by a spot urine protein:creatinine of 0.2 or greater, or
- baseline glucosuria (the presence of glucosuria).
- Schizophrenia Prodrome Criteria:
- We will be enrolling both Attenuated Positive Syndrome (APS) \[1\], Genetic Familial Risk (GFR) \[1\] and Clinically High Risk Negative (CHR-) symptom prodromes to this study. A separate analysis will be done for the APS and CHR- patients.
- Attenuated Positive Syndrome: One or more of the 5 SOPS positive items scoring in the prodromal range (rating of 3-5) AND Symptoms beginning within the past year or increasing 1 or more points within the past year AND Symptoms occurring at least once per wk for last month.
- Genetic Familial Risk: First degree relative with history of any psychotic disorder OR Criteria for schizotypal personality disorder met in patient AND GAF drop of at least 30% over the last month vs 1 year ago. In our experience, very few patients only meet criteria for this syndrome.
- CHR-: To make criteria, social isolation must be present along with either flat affect or impairment in the occupational role. Therefore to meet criteria for CHR-, Social Anhedonia (N1) has to be present at a score of 3 or above, and, in addition, one of the other two symptoms (N3 or N6) listed must also present at a minimum level of 3. Note: a score of "6" on these items is not considered exclusionary.
Exclusion
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2012
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT00826202
Start Date
March 1 2009
End Date
November 1 2012
Last Update
August 14 2017
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale University
New Haven, Connecticut, United States
2
Zucker Hillside Hospital
Glen Oaks, New York, United States
3
New York State Psychiatric Institute
New York, New York, United States, 10032
4
Nathan Kline Institute
Orangeburg, New York, United States, 10962